

## Program

**Self-paced learning package:** Available from Friday 19 July 2024

Topic and presenters		Learning objectives
Diagnostic tests and cellular therapies	<p><b>Diagnostic tests</b></p> <p><b>Dr Tamasine Stewart</b>, Haematology Laboratory Registrar, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Vic</p>	<ul style="list-style-type: none"> <li>Describe the different methodologies used in diagnosing haematological malignancies</li> <li>Explain the principles of fluorescence in situ hybridisation (FISH) and next generation sequencing (NGS)</li> <li>Explain the diagnostic tests required for establishing the diagnosis of haematological malignancies, focusing on acute leukaemia</li> </ul>
	<p><b>CAR T-cell therapy</b></p> <p><b>Dr Mark Dowling</b>, Cellular Therapies Fellow, Victorian Cancer Agency Mid-Career Fellow, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Vic</p>	<ul style="list-style-type: none"> <li>Describe the complex logistics involved in delivering CAR T-cell therapy</li> <li>Describe the standard-of-care indications for CAR T-cell therapy in Australia</li> <li>Overview the pivotal trials and expected outcomes in the approved indications</li> <li>Describe the pathophysiology and management of common CAR-T related toxicities, including cytokine release syndrome (CRS) and immune effector-cell associated neurotoxicity syndrome (ICANS)</li> </ul>
	<p><b>BMT</b></p> <p><b>Dr Ray Mun Koo</b>, Bone Marrow Transplant Fellow, Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Vic</p>	<ul style="list-style-type: none"> <li>Describe the basic principles of haematopoietic stem cell transplantation</li> <li>Explain the indications of haematopoietic stem cell transplantation.</li> <li>Explain the basic principles of</li> </ul>

		<p>conditioning therapy for haematopoietic stem cell transplantation</p> <ul style="list-style-type: none"> <li>Identify the most common toxicities of haematopoietic stem cell transplantation</li> </ul>
Non-malignant haematological disorders	<p><b>Immune thrombocytopenia</b></p> <p><b>Isaac Goncalves,</b> <i>Consultant Haematologist, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Vic</i></p>	<ul style="list-style-type: none"> <li>Describe the pathophysiology and diagnosis of immune thrombocytopenia</li> <li>Compare the efficacy and safety of treatment options for immune thrombocytopenia</li> </ul>
	<p><b>Haemophilia</b></p> <p><b>Antoinette Runge,</b> <i>Haematologist RBWH haemophilia unit</i></p>	<ul style="list-style-type: none"> <li>Describe pathophysiology of haemophilia, including the role of clotting factors and their deficiencies</li> <li>Understanding the different type haemophilia ( A, B etc) and their respective genetic causes</li> <li>Discuss haemophilia management including prophylactic and emergency treatment strategies</li> </ul>
Acute Myeloid Leukaemia (AML)	<p><b>Overview of Acute Myeloid Leukaemia</b></p> <p><b>Dr Andrew Wei,</b> <i>Stream Leader- Acute Leukaemia and MDS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Vic</i></p>	<ul style="list-style-type: none"> <li>Describe the pathophysiology of acute myeloid leukaemia</li> <li>Assess the prognostic impact of relevant cytogenetics or</li> <li>molecular mutations of acute myeloid leukaemia</li> </ul>

	<p><b>Management in young and fit patients</b></p> <p><b>Ashish Bajel</b>, <i>Disease Group Co-Lead – Acute Leukemia and MDS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Vic</i></p>	<ul style="list-style-type: none"> <li>• Explain treatment paradigm for acute myeloid leukaemia (AML) in young and fit patients</li> <li>• Describe the most commonly used treatment regimens for AML and their place in therapy</li> </ul>
	<p><b>Management in older or unfit patients</b></p> <p><b>Ashish Bajel</b>, <i>Disease Group Co-Lead – Acute Leukemia and MDS, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Vic</i></p>	<ul style="list-style-type: none"> <li>• Identify limitations of AML treatment in older/unfit patients</li> <li>• Describe treatment options for patients unfit for standard induction</li> <li>• Describe the most commonly used regimens for AML and understand their place in therapy</li> </ul>
<p><b>Acute Lymphoblastic Leukaemia (ALL)</b></p>	<p><b>Acute Lymphoblastic Leukaemia Biology and Diagnosis</b></p> <p><b>David Yeung</b>, <i>Haematologist, Royal Adelaide Hospital; Research Fellow, South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, SA</i></p>	<ul style="list-style-type: none"> <li>• Understand the basic clinical presentation of acute lymphoblastic leukaemia</li> <li>• Appreciate the principles of disease risk stratification and how this affect treatment decisions</li> </ul>
	<p><b>ALL overview and management of ALL in young and fit patients</b></p> <p><b>Dr Shaun Fleming</b>, <i>Clinical &amp; Laboratory Haematologist, Alfred Health, Melbourne, Vic</i></p>	<ul style="list-style-type: none"> <li>• Describe of the pathophysiology of acute lymphoblastic leukaemia</li> <li>• Appreciate the principles of disease risk stratification and how this affect treatment decisions</li> <li>• Understand treatment paradigm for acute lymphoblastic leukaemia in young and fit adult patients</li> <li>• Detail common complications from intense treatment regimens for acute lymphoblastic leukaemia</li> </ul>

	<p><b>Management of ALL in older or unfit patients</b></p> <p><b>Dr Shaun Fleming</b>, <i>Clinical &amp; Laboratory Haematologist, Alfred Health, Melbourne, Vic</i></p>	<ul style="list-style-type: none"> <li>• Understand treatment paradigm for acute lymphoblastic leukaemia in older or unit patients not appropriate for AYA protocols.</li> <li>• Describe the most commonly used regimens and understand their place in therapy Recognise limitations of treatment in older/unfit patients</li> </ul>
Lymphoma	<p><b>Diffuse large b-cell lymphoma</b></p> <p><b>Dr Nick Murphy</b>, <i>Consultant Haematologist, Royal Hobart Hospital, Tas</i></p>	<ul style="list-style-type: none"> <li>• Describe the pathophysiology of relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL)</li> <li>• Describe poor prognostic factors for DLBCL</li> <li>• Understand treatment options and approaches for RR DLBCL in Australia</li> <li>• Recognise emerging therapies in RR DLBCL</li> </ul>
	<p><b>CNS lymphoma</b></p> <p>Dr Aarya Murali, <i>Advanced trainee Haematology Princess Alexandra hospital, Qld</i></p>	<ul style="list-style-type: none"> <li>• Pathophysiology of CNS lymphoma including primary and secondary</li> <li>• Diagnosis and work up for CNS lymphoma</li> <li>• Principles of management and emerging therapies</li> </ul>
Relapsed/refractory Multiple Myeloma	<p><b>Prognosis</b></p> <p><b>Dr Michael Low</b>, <i>Consultant Haematologist, Myeloma Lead &amp; Head of Haematology training, Monash Health; Director of Physician Education Casey Hospital, Melbourne, Vic</i></p>	<ul style="list-style-type: none"> <li>• Describe the disease course of myeloma</li> <li>• Explain when to treat patients with multiple myeloma</li> <li>• Describe poor prognostic factors for multiple myeloma</li> <li>• Recognise the impact of treatment response on prognosis</li> </ul>

	<p><b>Treatment of relapsed/refractory multiple myeloma</b></p> <p><b>Dr Michael Low</b>, <i>Consultant Haematologist, Myeloma Lead &amp; Head of Haematology training, Monash Health; Director of Physician Education Casey Hospital, Melbourne, Vic</i></p>	<ul style="list-style-type: none"> <li>• Identify factors that impact treatment selection for patients with relapsed/refractory multiple myeloma</li> <li>• Rationalise combination therapy options based on mechanism of action</li> <li>• Evaluate different combination therapy treatment options for relapsed multiple myeloma</li> <li>• Recognise the role of BCMA targeting therapies and CAR-T in the treatment of relapsed/refractory multiple myeloma</li> </ul>
<p><b>Supportive care and toxicities</b></p>	<p><b>Supportive care in acute leukaemia</b></p> <p><b>Philip Selby</b>, <i>Senior Clinical Pharmacist, Haematology, Royal Adelaide Hospital; PHD Candidate, University of Adelaide, School of Medicine</i></p>	<ul style="list-style-type: none"> <li>• Recognise supportive care requirements in patients undergoing treatment for acute leukaemia</li> <li>• Recognise and understand how to manage potential drug interactions, problematic toxicities and practical issues with supportive care medications in acute leukaemia</li> <li>• Briefly describe differing supportive care requirements with different acute leukaemia treatment regimens</li> </ul>
	<p><b>Supportive care in bone marrow transplant</b></p> <p><b>Shevon Fernando</b>, <i>Senior Haematology Pharmacist, Alfred Health, Vic</i></p>	<ul style="list-style-type: none"> <li>• Explain the reasons supportive care is needed in bone marrow transplant.</li> <li>• Describe the role of antimicrobial prophylaxis in bone marrow transplant and the therapeutic agents utilised.</li> <li>• Outline preventative strategies for mucositis, neutropenia, hepatic sinusoidal obstruction syndrome in bone marrow transplant.</li> <li>• Discuss the principles of graft versus host disease and the therapeutic agents utilised for its prevention</li> </ul>

## Program

**Live seminar:** Saturday 31 August 2024

*All times listed are in AEST*

Time (AEST)	Session
0850-0900	<b>Online login available</b>
0900-0910	<p><b>Welcome, introduction, housekeeping</b></p> <p><b>Maggie Chau</b>, Clinical Pharmacist, Pharmacy Department, The Royal Melbourne Hospital, Vic  <b>Kristoffer Johnstone</b>, Advanced Pharmacist and Team leader - Cancer Care, Cairns Hospital, Cairns, Qld</p>
0910-0940	<p><b>Review of self-paced learning package material and Q&amp;A</b></p> <p><b>Maggie Chau</b>, Clinical Pharmacist, Pharmacy Department, The Royal Melbourne Hospital, Vic  <b>Kristoffer Johnstone</b>, Advanced Pharmacist and Team leader - Cancer Care, Cairns Hospital, Cairns, Qld</p>
0940-1100	<p><b>Case session 1: AML</b></p> <p><b>Led by: Maggie Chau</b>, Clinical Pharmacist, Pharmacy Department, The Royal Melbourne Hospital, Vic</p>
1100-1115	<p><b>Case session 1: Recap and Q&amp;A</b></p> <p><b>Led by: Maggie Chau</b>, Clinical Pharmacist, Pharmacy Department, The Royal Melbourne Hospital, Vic</p>
1115-1130	<b>Break</b>
1130-1245	<p><b>Case session 2: Haemophilia</b></p> <p><b>Led by: Kristoffer Johnstone</b>, Advanced Pharmacist and Team leader - Cancer Care, Cairns Hospital, Cairns, Qld</p>

1245-1300	<p><b>Case session 2: Recap and Q&amp;A</b></p> <p><b>Led by: Kristoffer Johnstone</b>, <i>Advanced Pharmacist and Team leader - Cancer Care, Cairns Hospital, Cairns, Qld</i></p>
1300-1330	<b>Lunch Break</b>
1330-1430	<p><b>Case session 3: CNS lymphoma</b></p> <p><b>Led by: Kristoffer Johnstone</b>, <i>Advanced Pharmacist and Team leader - Cancer Care, Cairns Hospital, Cairns, Qld</i></p>
1430-1440	<p><b>Case session 3: Recap and Q&amp;A</b></p> <p><b>Led by: Kristoffer Johnstone</b>, <i>Advanced Pharmacist and Team Leader - Cancer Care, Cairns Hospital, Cairns, Qld</i></p>
1440-1540	<p><b>Case session 4: RR Multiple myeloma</b></p> <p><b>Led by: Vivian Day</b>, <i>Advanced Pharmacist and Team Leader - Cancer Care, Royal Brisbane and Women's Hospital, Brisbane, Qld</i></p>
1540-1550	<p><b>Case session 4: Recap and Q&amp;A</b></p> <p><b>Led by: Vivian Day</b>, <i>Advanced Pharmacist and Team Leader - Cancer Care, Royal Brisbane and Women's Hospital, Brisbane, Qld</i></p>
1550-1600	<b>Break</b>
1600-1645	<p><b>Recap and Q&amp;A with competition quiz</b></p> <p><b>Maggie Chau</b>, <i>Clinical Pharmacist, Pharmacy Department, The Royal Melbourne Hospital, Vic</i>  <b>Kristoffer Johnstone</b>, <i>Advanced Pharmacist and Team leader - Cancer Care, Cairns Hospital, Cairns, Qld</i></p>
1645-1650	<b>Close of live virtual seminar</b>

Please note: presentation recordings from the live virtual seminar will not be available.